Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the expansion of its artificial intelligence (AI) capability with...

Related Keywords

Japan ,Belgium ,Canada ,Vienna ,Wien ,Austria ,Australia ,United States ,Switzerland ,Melbourne ,Victoria ,United Kingdom ,Australian ,Mark Europe ,Thomas Beyer ,Michael Wheatcroft ,Dedicaid Gmbh ,Head Of The Research Domain Quantitative Imaging ,Prnewswire Telix Pharmaceuticals Limited ,University Vienna ,Telix Pharmaceuticals Limited Disclosure Committee ,Drug Administration ,Linkedin ,Australian Therapeutic Goods Administration ,Telix Pharmaceuticals ,Health Canada ,Australian Securities Exchange ,Pharmaceuticals Limited ,Vienna Based Dedicaid Gmbh ,Medical University ,Medical University Vienna ,United States Food ,Chief Scientist ,Research Domain ,Quantitative Imaging ,Medical Physics ,Listing Rule ,Telix Pharmaceuticals Limited ,Nucl Med ,